Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen
Vishwanath, Shilpa, MS, Baroody, Fuad M., MD, Chaaban, Mohamad R., MD, deTineo, Marcella, BSN, Lasser, Kenneth H., MD, Lasser, Elliot C., MD, Naclerio, Robert M., MD
Published in Journal of allergy and clinical immunology (01.07.2011)
Published in Journal of allergy and clinical immunology (01.07.2011)
Get full text
Journal Article